Adastra Holdings Past Earnings Performance
Past criteria checks 0/6
Adastra Holdings has been growing earnings at an average annual rate of 5.4%, while the Pharmaceuticals industry saw earnings growing at 44.1% annually. Revenues have been growing at an average rate of 60.6% per year.
Key information
5.4%
Earnings growth rate
17.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 60.6% |
| Return on equity | -25.0% |
| Net Margin | -14.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Market Cool On Adastra Holdings Ltd.'s (CSE:XTRX) Revenues Pushing Shares 26% Lower
Sep 08
Is Adastra Holdings (CSE:XTRX) A Risky Investment?
Sep 04Adastra Holdings Ltd. (CSE:XTRX) Might Not Be As Mispriced As It Looks After Plunging 41%
Jul 11Adastra Holdings Ltd. (CSE:XTRX) Might Not Be As Mispriced As It Looks After Plunging 27%
May 08Adastra Holdings Ltd.'s (CSE:XTRX) Shares Leap 26% Yet They're Still Not Telling The Full Story
Mar 08Adastra Holdings Ltd.'s (CSE:XTRX) Shares Not Telling The Full Story
Jan 23Here's Why Adastra Holdings (CSE:XTRX) Can Afford Some Debt
Sep 28Subdued Growth No Barrier To Adastra Holdings Ltd.'s (CSE:XTRX) Price
Aug 03Does Adastra Holdings (CSE:XTRX) Have A Healthy Balance Sheet?
Jan 13We Think Adastra Holdings (CSE:XTRX) Has A Fair Chunk Of Debt
Sep 28Does Adastra Holdings (CSE:XTRX) Have A Healthy Balance Sheet?
Mar 23Here's Why Adastra Holdings (CSE:XTRX) Can Afford Some Debt
Dec 07Here's Why Phyto Extractions (CSE:XTRX) Can Afford Some Debt
Aug 18Auditors Have Doubts About Phyto Extractions (CSE:XTRX)
May 04Adastra Labs Holdings (CSE:XTRX) Is Making Moderate Use Of Debt
Dec 10Revenue & Expenses Breakdown
How Adastra Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 23 | -3 | 9 | 0 |
| 31 Mar 24 | 23 | -5 | 10 | 0 |
| 31 Dec 23 | 22 | -4 | 9 | 0 |
| 30 Sep 23 | 21 | -5 | 9 | 0 |
| 30 Jun 23 | 21 | -5 | 8 | 0 |
| 31 Mar 23 | 17 | -4 | 7 | 0 |
| 31 Dec 22 | 13 | -4 | 6 | 0 |
| 30 Sep 22 | 11 | -3 | 7 | 0 |
| 30 Jun 22 | 9 | -3 | 6 | 0 |
| 31 Mar 22 | 7 | -3 | 5 | 0 |
| 31 Dec 21 | 6 | -3 | 4 | 0 |
| 30 Sep 21 | 5 | -1 | 2 | 0 |
| 30 Jun 21 | 4 | -5 | 5 | 0 |
| 31 Mar 21 | 3 | -5 | 5 | 0 |
| 31 Dec 20 | 2 | -8 | 8 | 0 |
| 30 Sep 20 | 1 | -11 | 8 | 0 |
| 30 Jun 20 | 0 | -7 | 5 | 0 |
| 31 Mar 20 | 0 | -7 | 4 | 0 |
| 31 Dec 19 | 0 | -4 | 2 | 0 |
| 31 Oct 19 | 0 | -2 | 1 | 0 |
| 31 Jul 19 | 0 | -1 | 1 | 0 |
Quality Earnings: XTRX is currently unprofitable.
Growing Profit Margin: XTRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XTRX is unprofitable, but has reduced losses over the past 5 years at a rate of 5.4% per year.
Accelerating Growth: Unable to compare XTRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XTRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Return on Equity
High ROE: XTRX has a negative Return on Equity (-24.99%), as it is currently unprofitable.